NCT01574170View on ClinicalTrials.gov

Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival

PHASE4CompletedINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

June 18, 2012

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
Metastatic Breast Cancer Starting a Third Line Chemotherapy
Interventions
OTHER

Construction of a prognostic score (non-drug intervention types)

Record of clinical, histological and biological data and questionnaires data in patients starting a third line metastatic until progression

Trial Locations (16)

12000

Centre Hospitalier de Rodez, Rodez

21000

Centre d'Oncologie et de Radiothérapie du Parc, Dijon

21079

Centre Georges François Leclerc, Dijon

25030

CHU Jean Minjoz, Besançon

26609

CHRU Brest, Brest

31000

CHU Rangueil, Toulouse

31052

Institut Claudius Regaud, Toulouse

31130

Clinique La Croix du Sud, Quint-Fonsegrives

35042

Centre Eugène Marquis, Rennes

46005

Centre Hospitalier Jean Rougier, Cahors

49933

Institut de Cancérologie de l'Ouest Paul Papin, Angers

54519

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

65000

Polyclinique de l'Ormeau, Tarbes

67065

Centre Paul Strauss, Strasbourg

81000

C.M.C.O. Claude Bernard, Albi

81108

Centre Hospitalier Intercommunal de Castres-Mazamet, Castres

All Listed Sponsors
lead

Institut Claudius Regaud

OTHER

NCT01574170 - Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival | Biotech Hunter | Biotech Hunter